BETA: Please send your feedback!
PTC Therapeutics
PTCT:NAS
Biotechnology
$2.25bn
SMALL cap
$36.50
(0.22%)
0.09%
since start of 2019
-8.99
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 3
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1998
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. It is focused on developing treatments to fundamentally change the lives of patients living with rare genetic disorders. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
website
Headquarters
Executives
| Name | Title | Gender |
| Michael Schmertzler, MBA | Chairman | Male |
| Stuart W. Peltz, PhD | Chief Executive Officer & Class I Director | Male |
| Mark Elliott Boulding | Secretary, Chief Legal Officer & Executive VP | Male |
| Allan Steven Jacobson, PhD | Independent Class III Director | Male |
| Martin Rexroad | Senior Vice President-Human Resources | Male |
| Jane Baj | Head-Investor Relations | Female |
| Neil Gregory Almstead, PhD | Executive VP-Research, Operations & Technology | Male |
| Shane William Charles Kovacs, CFA, MBA | CFO & Head-Corporate Development | Male |
| Tuyen Ong, MD, MBA | Chief Medical Officer | null |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
PTC Therapeutics - Competitors and Related Companies
How PTC Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.
PTC Therapeutics
PTCT:NAS
Biotechnology
$2.25bn
SMALL cap
$36.50
(0.22%)
0.09%
since start of 2019
-8.99
Fate Therapeutics
FATE:NAS
Biotechnology
$1.09bn
SMALL cap
$14.52
(0.89%)
0.07%
since start of 2019
-11.88
Retrophin
RTRX:NAS
Biotechnology
$488.82mm
SMALL cap
$11.38
(0.14%)
-0.49%
since start of 2019
-3.32
Xencor
XNCR:NAS
Biotechnology
$2.05bn
SMALL cap
$36.26
(1.18%)
0.01%
since start of 2019
41.67
Sarepta Therapeutics
SRPT:NAS
Biotechnology
$6.43bn
MID cap
$86.50
(0.73%)
-0.19%
since start of 2019
-10.80
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
$59.70mm
MEGA cap
$2.29
(-0.04%)
1.36%
since start of 2019
-2.39